Healthcare / Medical DevicesTokyo
$224.00
-25.00 (-10.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-313.4M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.8B
P/E
28.3x
↑EV/EBITDA
14.1x
↑ROE
13.0%
↑Gross Margin
86.7%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.4%
FCF CAGR
—
FCF margin
-24.8%
FCF / Net income
-1.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.36B · net income $205.8M · FCF $-336.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.36B | $1.36B | $673.5M | $954.7M | $640.9M |
| Net Income | $205.8M | $205.8M | $-641.3M | $90.2M | $153.3M |
| EBITDA | $310.9M | $310.9M | $-599.6M | $184.2M | $241.1M |
| EPS | 7.92 | 7.92 | -5.15 | 3.52 | 6.77 |
| Gross Margin | 86.7% | 86.7% | 3.2% | 75.3% | 86.9% |
| Operating Margin | 17.4% | 17.4% | -96.4% | 17.5% | 21.2% |
| Net Margin | 15.2% | 15.2% | -95.2% | 9.4% | 23.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.09 | 0.07 | 0.30 |
| Current Ratio | 3.15 | 3.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-336.5M | $-336.5M | $-313.4M | $-20.3M | $582.7M |
| Returns | |||||
| ROE | 13.0% | 13.0% | -46.9% | 4.6% | 20.6% |
| Valuation | |||||
| P/E | 28.28 | 28.28 | — | 230.97 | — |
| EV/EBITDA | 14.06 | 14.06 | — | 102.11 | — |
| P/B | 3.67 | 3.67 | 6.27 | 10.68 | — |
| Growth & Yield | |||||
| Revenue Growth | 101.5% | 101.5% | -29.5% | 49.0% | — |
| EPS Growth | 253.8% | 253.8% | -246.3% | -48.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
35.9%
EPS terminal req.
$19.88
Spread vs growth
217.9%
5Y implied EPS CAGR
24.9%
EPS terminal req.
$24.05
Spread vs growth
228.9%
10Y implied EPS CAGR
17.2%
EPS terminal req.
$38.73
Spread vs growth
236.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.15 → 7.92
Residual
-40.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.